Minnesota Oncology

Lung Cancer - Non-Small Cell News

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising (August 29, 2014)

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is... Continue Reading

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors (August 5, 2014)

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped... Continue Reading

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer (August 4, 2014)

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC).... Continue Reading

Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC (June 5, 2014)

A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (Taxotere... Continue Reading

CO-1686 Lung Cancer Treatment Receives Breakthrough Designation by FDA (May 21, 2014)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, NSCLC accounts for 75–80% of all lung cancers. Although progress has been made in recent years the majority of patients with advanced stage lung cancer still... Continue Reading

Preoperative Chemotherapy Improves Survival in NSCLC (May 2, 2014)

Pre-operative (neoadjuvant) chemotherapy for non-small cell lung cancer (NSCLC) is associated with a significant reduction in the risk of death, according to the results of a meta-analysis published in The Lancet. Lung cancer remains the leading cause... Continue Reading

Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal of Medicine. Lung cancer is the leading cause... Continue Reading

Nintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC (March 6, 2014)

Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced non-small cell lung cancer previously treated with one line of platinum-based therapy, according to the results of a study published in The Lancet... Continue Reading

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Latest Lung Cancer - Non-Small Cell News By Stage


Recurrent Lung Cancer - Non-Small Cell

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising (August 29, 2014)

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is... Continue Reading

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors (August 5, 2014)

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped... Continue Reading

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer (August 4, 2014)

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC).... Continue Reading

Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC (June 5, 2014)

A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (Taxotere... Continue Reading

Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal of Medicine. Lung cancer is the leading cause... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

Screening/Prevention Lung Cancer - Non-Small Cell

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung... Continue Reading

Screening Could Reduce Lung Cancer Mortality (April 24, 2013)

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading

Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)

Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading

Diesel Exhaust Linked to Lung Cancer (June 26, 2012)

Diesel exhaust is associated with an increased risk of lung cancer, according to a press release issued by the World Health Organization (WHO).[1] The announcement came after a group of international experts gathered for a weeklong meeting to review the... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Stages I-IIIA Lung Cancer - Non-Small Cell

Preoperative Chemotherapy Improves Survival in NSCLC (May 2, 2014)

Pre-operative (neoadjuvant) chemotherapy for non-small cell lung cancer (NSCLC) is associated with a significant reduction in the risk of death, according to the results of a meta-analysis published in The Lancet. Lung cancer remains the leading cause... Continue Reading

Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (June 12, 2013)

In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading

Stereotactic Body Radiation Improves Lung Cancer Survival (November 9, 2012)

Stereotactic body radiation for early-stage, inoperable non-small cell lung cancer yields high overall survival rates and low toxicity compared to conventional radiotherapy, according to the results of a study presented at the annual meeting of the American... Continue Reading

Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)

Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading

Higher Radiation Dose Does Not Benefit Lung Cancer Patients (October 13, 2011)

Among patients with Stage III non-small cell lung cancer, treatment with a higher dose of radiation therapy does not result in better overall survival than a standard dose of radiation therapy. These results were presented at the 53rd Annual Meeting of... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages IIIB-IV Lung Cancer - Non-Small Cell

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising (August 29, 2014)

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is... Continue Reading

Gilotrif combined with Erbitux Benefits Non-Small Cell Lung Cancer Patients Resistant to EGFR Inhibitors (August 5, 2014)

Researchers recently reported that a combination of the epidermal growth factor receptor (EGFR) targeted agents Gilotrif® (afatinib) and Erbitux® (cetuximab) were able to effectively shrink EGFR positive non-small cell lung (NSCLC)cancer that had stopped... Continue Reading

Pembrolizumab Appears Promising in Treatment of Non-Small Cell Lung Cancer (August 4, 2014)

Results from an ongoing Phase Ib study indicate that treatment with the experimental anti-PD-1 antibody pembrolizumab resulted in high response rates and slowed cancer progression in previously untreated stage IV non–small cell lung cancer (NSCLC).... Continue Reading

Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC (June 5, 2014)

A phase III randomized trial has shown that Cyramza™ (ramucirumab) combined with Taxotere® (docetaxel) extended overall survival 1.4 months in patients with non-small cell lung cancer (NSCLC) when compared to standard second-line therapy (Taxotere... Continue Reading

Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal of Medicine. Lung cancer is the leading cause... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell